中國升海集團(01676.HK)成立合資公司於香港經營高需求手機及電子產品B2B貿易平台
格隆匯3月16日丨中國升海集團(01676.HK)公佈,於2022年3月16日,公司及CS Business Solutions訂立協議,於香港成立合資公司,並於香港經營高需求手機及電子產品B2B貿易平台,及B2B供應鏈金融業務。合資公司將由公司及CS Business Solutions分別擁有55%及45%。
CS Business Solutions主要於香港從事物流業務。董事認為合資公司具有良好增長潛力,並將成為集團現有業務具附加值的配套。董事亦認為成立合資公司對公司及其股東有利。成立後,合資公司將成為公司的非全資附屬公司,而合資公司的財務資料將於集團賬目內合併入賬。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.